首页> 外文期刊>Journal of Drug Delivery and Therapeutics >EFFECT OF ORAL IRON THERAPY ON CLINICAL OUTCOMES IN PATIENTS WITH HEART FAILURE
【24h】

EFFECT OF ORAL IRON THERAPY ON CLINICAL OUTCOMES IN PATIENTS WITH HEART FAILURE

机译:口服铁疗法对心力衰竭患者临床疗效的影响

获取原文
           

摘要

Background- Earlier studies have shown that anemia in heart failure (HF) patients decreases exercise tolerance/capacity, functional status and quality of life. We studied the effect of oral iron supplementation in anemic patients with HF. Methods – We assigned 60 anemic (Hb 8—11g/dl) patients with HF (NYHA class II&III) with LVEF <40% in to 2 groups. Group- I- received ferrous sulfate 100mg bid x 90 days +standard treatment for HF. Group-II-received standard treatment for HF. Primary end points of the study were exercise tolerance(6-min walk distance), quality of life(MLHFQ ) and haematological parameters. Secondary end points- Borg scale for dyspnoea and fatigue efficacy , safety assessment and few haematological parameters. Results- There was significant improvement in exercise tolerance/ capacity and quality of life in iron treated patients as compared to control group (group – II). Dyspnoea and fatigue were reduced . Haematological parameters(Hb, RC, MCV, MCH, MCHC PCV &RBC count) increased gradually in iron treated patients with HF as compared to control group. However, incidence of microcytic- hypochromic anemia was reduced in group –I. Orally administered iron was well tolerated with mild side effects in anemic patients with HF. Conclusion - Oral iron supplementation in HF patients with anemia improves exercise tolerance/capacity, quality of life, dyspnoea , fatigue and various haematological parameters.
机译:背景-较早的研究表明,心力衰竭(HF)患者的贫血会降低运动耐力/能力,功能状态和生活质量。我们研究了口服铁剂在贫血性HF患者中的作用。方法–我们将60名LVEF <40%的贫血(Hb 8-11g / dl)HF患者(NYHA II&III级)分为两组。第I组-接受硫酸亚铁100mg bid x 90天+ HF的标准治疗。 II组收到的HF的标准治疗方法。该研究的主要终点是运动耐力(步行6分钟),生活质量(MLHFQ)和血液学参数。次要终点-呼吸困难和疲劳功效的Borg量表,安全性评估和少量血液学参数。结果:与对照组相比,铁治疗的患者的运动耐力/运动能力和生活质量有了显着改善(II组)。呼吸困难和疲劳减轻。与对照组相比,铁治疗的HF患者的血液学指标(Hb,RC,MCV,MCH,MCHC PCV和RBC计数)逐渐增加。但是,在第I组中,小细胞性贫血性贫血的发生率降低了。贫血贫血患者口服铁剂耐受性良好,且副作用轻微。结论-HF贫血患者口服铁补充剂可改善运动耐力/能力,生活质量,呼吸困难,疲劳和各种血液学参数。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号